# Ciprofibrate and Pre-diabetes

> **NCT03662984** · PHASE3 · COMPLETED · sponsor: **Maastricht University Medical Center** · enrollment: 11 (actual)

## Conditions studied

- Myocardial Insulin Sensitivity
- Impaired Glucose Metabolism
- Diastolic Dysfunction

## Interventions

- **DRUG:** Ciprofibrate 100Mg Tablet
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT03662984
- **Lead sponsor:** Maastricht University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-01
- **Primary completion:** 2020-11-06
- **Final completion:** 2020-11-13
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2021-01-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03662984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03662984, "Ciprofibrate and Pre-diabetes". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03662984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*